BBOT Form 3 Filing: Director Declares No Securities Held

Rhea-AI Filing Summary

Kumar Neil is identified as a director of BridgeBio Oncology Therapeutics, Inc. (ticker: BBOT) on an initial Section 16 Form 3. The filing states that the reporting person does not beneficially own any securities of the issuer and references an executed power of attorney (Exhibit 24). The form reports the filing was made by one reporting person and is an initial statement of beneficial ownership.

Positive

• Form 3 filed by reporting person, confirming compliance
• Statement explicitly declares no beneficial ownership
• Exhibit 24 (Power of Attorney) included, indicating authorized filing

Negative

• None.

Insights

Securities Compliance Analyst

TL;DR: A director-filed Form 3 disclosing no beneficial ownership, meeting Section 16 initial-reporting obligations.

The filing formally records the relationship between the reporting person and the issuer and states that no equity or derivative positions are beneficially owned. From a compliance perspective, the presence of Exhibit 24 (power of attorney) and a signed submission indicate procedural completeness. The disclosure itself is neutral for investors because it reports absence of holdings rather than any transfer or ownership that would affect share supply or insider incentives.

Corporate Governance Specialist

TL;DR: Initial disclosure by a director showing no holdings is a routine governance filing and carries no material market impact.

This Form 3 documents the reporting relationship and affirms no direct or indirect ownership of the issuer's securities. It satisfies transparency expectations under Section 16 but does not provide information that would alter assessments of insider alignment or potential conflicts of interest, since no positions are reported.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Aaron Chan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the reporting person on this Form 3 for BBOT?

The reporting person is Kumar Neil, identified as a Director of BridgeBio Oncology Therapeutics, Inc. (BBOT).

Does the Form 3 report any securities beneficially owned by the reporting person?

No. The filing states no securities are beneficially owned by the reporting person.

What exhibits or authorizations are referenced in the filing?

The filing references Exhibit 24 – Power of Attorney and includes an executed signature block.

What is the date of the event requiring the statement listed on the form?

The form lists the date of the event requiring the statement as 08/11/2025.

When was the Form 3 signed on behalf of the reporting person?

The signature block shows the form was executed by an attorney-in-fact on 08/18/2025.